SystImmune, Inc. Announces the Presentation of Breast Cancer Clinical Trial Results at the 2023 San Antonio Breast Cancer Conference and US Clinical Trial Developments

Posted on by

REDMOND, Wash., Dec. 5, 2023 /PRNewswire/ — SystImmune, Inc (SystImmune), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) authorized the company to proceed with the planned clinical study of the HER2-specific HIRE platform ADC,…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.